Peptide Therapeutics
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Bioorganic Chemistry".
Deadline for manuscript submissions: closed (10 October 2017) | Viewed by 96696
Special Issue Editors
2. Department of Organic Chemistry, University of Barcelona, Barcelona, Spain
Interests: antimicrobial peptides; solid-phase chemistry; combinatorial chemistry; drug delivery systems; peptide drug conjugates; orthogonal chemistry; drug discovery; biomaterials
Special Issues, Collections and Topics in MDPI journals
Interests: peptides; solid-phase synthesis; cell penetrating peptides; antimicrobial peptides; oligonucleotides; peptide nucleic acids; drug discovery; peptide–drug conjugates
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
During the last few years, the role of peptides in the drug discovery arena have been increased enormously, and, every year, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approve several of these chemical entities as new drugs. It is interesting to analyze the peptide–amino-acid-based drugs accepted by the FDA in 2016 (Molecules, 22, 368; doi:10.3390/molecules22030368 (2017)). Adlyxin (Lixisenatide) is a 44-amino acid peptide, which can be considered as a small protein prepared by chemical methods, is a glucagon-like peptide (GLP-1). At the opposite end of the complexity point of view, Xiidra (Lifitegrast), which is recommended for dry eye disease, in an acyl dipeptide formed by two non-natural amino acids. During 2016, the FDA approved two amino acid derivatives: Briviact (Brivaracetam) and Auxim (Fluciclovine f-18) for epilepsy and as a diagnostic agent in Positron emission tomography (PET) imaging for cancer. This is an excellent example of the diversity of our field, in terms of both chemical structure and target therapeutics.
However, even more important than the number of chemical entities accepted by agencies is the large number of peptides that are presently in clinical trials. Furthermore, peptides, in addition to being an active pharmaceutical ingredient (API), are being used as shuttles to overcome some barriers, and are also used as linkers to bind together two moieties in the same drug, as occurs in antibody drug conjugates (ADC).
This Special Issue of Molecules aims to reflect the wonderful world surrounding peptides as therapeutics.
Prof. Fernando Albericio
Prof. Beatriz G. de la Torre
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- therapeutic peptides
- solid-phase peptide synthesis
- antimicrobial peptides
- peptides and Alzheimer disease
- peptides and metabolic syndrome
- peptides and cancer
- peptides as shuttles
- peptide based drug delivery
- peptide based vaccines
- peptides drug conjugates
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.